Cytokinetics (CYTK) RBC Capital Markets Global Healthcare Conference 2026 summary

Commercial performance and market dynamics

• MYKORZO launch metrics have surpassed expectations, with strong month-over-month growth and high physician awareness and intention to prescribe.

• Over 95% of patients starting therapy are treatment-naive, with a focus on new patient starts rather than competitive switches.

• REMS program features, such as a flexible two-to-eight-week echo monitoring window and no DDI requirement, are well received by physicians and support differentiation.

• Early friction with REMS system access has been addressed, improving operational efficiency for prescribers.

• Persistency and compliance rates are expected to be high, with projections of 70%-80% of patients remaining on therapy after one year.

Payer access and international expansion

• Medicare access is nearing parity with competitors, expected to reach full parity in Q2; commercial coverage is approaching 50% and targeted for parity in Q4.

• European launch is underway, starting with Germany, with reimbursement as the key hurdle; price in Europe is expected to be about 15% of the U.S. price.

• Most-Favored-Nation (MFN) policy is being monitored, but anticipated impact is minimal; company is proceeding with European and Japanese launches.

Pipeline and regulatory updates

• MAPLE-HCM sNDA aims to expand MYKORZO penetration in oHCM by supporting monotherapy use and potentially influencing treatment guidelines.

• ACACIA-HCM trial met both endpoints, showing significant benefits in symptoms and exercise capacity for nHCM, with robust secondary endpoint support.

• Long-term extension data suggest persistent benefit, and further data on remodeling and heterogeneity are forthcoming.

• Epidemiology data indicate a roughly equal split between oHCM and nHCM, with both populations representing significant commercial opportunities.